"Global Adalimumab Market – Industry Trends and Forecast to 2029
Global Adalimumab Market, By Drug class (Antirheumatics, TNF Alfa Inhibitors, Others), Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Oral, Parenteral, Others), Age Group (Pediatric, Adult, Geriatric), Dosage Form (Tablet, Injection, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Data Bridge Market Research analyses that the adalimumab market was valued at USD 20,912.1 million in 2021 and is expected to reach USD 31,610.01 million by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-adalimumab-market
Adalimumab is a prescription medicine which is sold under the brand names Humira and Exemptia. heumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, and ulcerative colitis are all treated with adalimumab. TNF (tumour necrosis factor alpha) is commonly bound by adalimumab. When TNF interacts to TBF receptors, an inflammatory response to autoimmune illness is triggered. By binding to a TNF, adalimumab reduces the likelihood of an inflammatory response.
**Segments**
- By Indication:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Plaque Psoriasis
- Ankylosing Spondylitis
- Crohn's Disease
- Ulcerative Colitis
- Others
- By Dosage Form:
- Pre-Filled Syringe
- Pre-filled Pen
- By Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
**Market Players**
- AbbVie Inc.
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Novartis AG
- Biogen
- Johnson Johnson Services, Inc.
- GlaxoSmithKline plc
- Merck Co., Inc.
- Sandoz International GmbH
The global adalimumab market is segmented based on indication, dosage form, and distribution channel. By indication, the market is further classified into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and others. Adalimumab is widely used in the treatment of autoimmune disorders like rheumatoid arthritis and inflammatory diseases such as Crohn's disease and ulcerative colitis. The dosage form segment includes pre-filled syringes and pre-filled pens, offering convenience and ease of use for patients. In terms of distribution channels, the market is divided into retail pharmacies, hospital pharmacies, and online pharmacies, providing accessibility to patients globally. The rising incidence of autoimmune diseases and the increasing preference for biologic therapies are driving the growth of the adalimumab market.
Key market players in the adalimumab market include AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Pfizer Inc., Novartis AG, Biogen, Johnson Johnson Services, Inc., GlaxoSmithThe global adalimumab market is highly competitive, with key players constantly striving to innovate and differentiate their products to gain a competitive edge. AbbVie Inc. is one of the leading players in the market with its flagship product Humira, which is one of the top-selling biologic drugs globally. AbbVie's strong market presence and extensive research and development efforts have enabled it to maintain its position in the adalimumab market. Amgen Inc. is another key player known for its innovative therapies in the autoimmune and inflammatory disease space. The company's focus on developing biologics has contributed to its strong presence in the adalimumab market.
Boehringer Ingelheim International GmbH is also a significant player in the adalimumab market, with a diverse portfolio of products targeting autoimmune diseases. The company's commitment to research and development has led to the introduction of novel treatment options for patients with conditions such as rheumatoid arthritis and psoriatic arthritis. Pfizer Inc. is another prominent player in the market, with a strong presence in the biologics segment. The company's investment in research and development has resulted in the development of innovative therapies for autoimmune diseases, further solidifying its position in the adalimumab market.
Novartis AG is a key player known for its focus on breakthrough therapies in various therapeutic areas, including autoimmune diseases. The company's portfolio of biologic drugs targeting conditions such as plaque psoriasis and ankylosing spondylitis has garnered significant market share in the adalimumab market. Biogen is another major player in the market, with a strong emphasis on research and development in neurology and immunology. The company's biologic therapies for autoimmune disorders have positioned it as a key player in the adalimumab market.
Johnson Johnson Services, Inc. is a renowned player in the pharmaceutical industry, with a diverse portfolio of products catering to various therapeutic areas. The company's presence in the adalimumab market**Global Adalimumab Market**
- **Drug Class:** Antirheumatics, TNF Alfa Inhibitors, Others
- **Indication:** Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others
- **Type:** Biologics, Biosimilars
- **Dosage Strength:** 40mg/0.4ml, 80mg/0.8ml, 20mg/0.2ml, 10mg/0.1ml, Others
- **Drug Type:** Branded, Generics
- **Route of Administration:** Oral, Parenteral, Others
- **Age Group:** Pediatric, Adult, Geriatric
- **Dosage Form:** Tablet, Injection, Solution, Others
- **End-Users:** Hospitals, Specialty Clinics, Homecare, Others
- **Distribution Channel:** Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
The global adalimumab market is witnessing significant growth due to the rising prevalence of autoimmune disorders and inflammatory conditions worldwide. The market segmentation based on drug class, indication, type, dosage strength, drug type, route of administration, age group, dosage form, end-users, and distribution channels provides a comprehensive understanding of the
Core Objective of Adalimumab Market:
Every firm in the Adalimumab Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.
- Size of the Adalimumab Market and growth rate factors.
- Important changes in the future Adalimumab Market.
- Top worldwide competitors of the Market.
- Scope and product outlook of Adalimumab Market.
- Developing regions with potential growth in the future.
- Tough Challenges and risk faced in Market.
- Global Adalimumab top manufacturers profile and sales statistics.
Highlights of TOC:
Chapter 1: Market overview
Chapter 2: Global Adalimumab Market
Chapter 3: Regional analysis of the Global Adalimumab Market industry
Chapter 4: Adalimumab Market segmentation based on types and applications
Chapter 5: Revenue analysis based on types and applications
Chapter 6: Market share
Chapter 7: Competitive Landscape
Chapter 8: Drivers, Restraints, Challenges, and Opportunities
Chapter 9: Gross Margin and Price Analysis
How the Report Aids Your Business Discretion?
- This section of this Market report highlights some of the most relevant factors and growth enablers that collectively ensure a high-end growth spurt
- The report unravels details on pronounced share assessments across both country-wise as well as region-based segments
- A leading synopsis of market share analysis of dynamic players inclusive of high-end industry veterans
- New player entry analysis and their scope of new business models
- The report includes strategic recommendations for new business veterans as well as established players seeking novel growth avenues
- A detailed consultation services based on historical as well as current timelines to ensure feasible forecast predictions
- A thorough evaluation and detailed study of various segments as well as sub-segments across regional and country-specific developments
- Details on market estimations, market size, dimensions
- A review of market competitors, their high-end product and service portfolios, dynamic trends, as well as technological advances that portray high end growth in this Market
Browse Trending Reports:
Anaesthesia Monitoring Devices Market
Silanes And Silicones Market
Catalyst Carriers Market
Ldpe Wax Market
Thermoplastic Polyurethane Tpu Films Market
Diabetic Gastroparesis Treatment Market
Anastomosis Device Market
Diabetic Food Market
Agricultural Films And Bonding Market
Automotive Relay Market
e Series Glycol Ether Market
Brachytherapy Isotopes Market
Cysticercosis Treatment Market
Diuretic Drugs Market
Cloud Assurance Market
Diagnostic Tape Market
Disinfecting Port Protectors Market
Feed Processing Market
Carbon Fiber Tape Market
Automotive Variable Oil Pump Market
Automation Identification System Market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 614 591 3140
UK: +44 845 154 9652
APAC : +653 1251 975
